The Beta 1 Adrenergic Receptor pipeline drugs market research report outlays comprehensive information on the Beta 1 Adrenergic Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Beta 1 Adrenergic Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Ophthalmology, Immunology, and Non Malignant Disorders which include the indications Congestive Heart Failure (Heart Failure), Idiopathic (Essential) Hypertension, Ocular Hypertension, Open-Angle Glaucoma, Anaphylaxis, and Infantile Hemangiomas. It also reviews key players involved in Beta 1 Adrenergic Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Beta 1 Adrenergic Receptor pipeline targets constitutes close to 41 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 1, 1, 12, 9, 4, 3, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 5 molecule.
Beta 1 Adrenergic Receptor overview
The beta-1 adrenergic receptor (β1-AR), also known as ADRB1, is a G protein-coupled receptor (GPCR) that is primarily expressed in the heart, where it plays a critical role in regulating cardiac function. It is also found in other tissues, such as the kidney, adipose tissue, and the juxtaglomerular apparatus of the kidney. Beta-1 ARs are activated by catecholamines such as epinephrine and norepinephrine, which are released by the adrenal medulla in response to stress or exercise.
For a complete picture of Beta 1 Adrenergic Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
